Skip to main content

Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales

The first-quarter results come as Merck shows substantial progress in preparing for Keytruda's patent expiration in 2028.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.